Eckert & Ziegler
Eckert & Ziegler focuses on isotope technology applications in cancer therapy, industrial radiometry, and nuclear medical diagnostics and therapy.
- Public
Eckert & Ziegler focuses on isotope technology applications in cancer therapy, industrial radiometry, and nuclear medical diagnostics and therapy.
ezag.comCrawled Oct 25, 2026
Eckert & Ziegler is a trusted supplier of stable and radioactive isotopes, and other engineered materials.
Eckert & Ziegler provides its customers with a complete service chain. From the acceptance and disposal of radioactive materials to the conditioning of radioactive residues to transportation, logistics and dismantling.
Below you will find an overview of the range of products and services in the Isotope Products segment.
Eckert & Ziegler focuses on applications in cancer therapy, industrial radiometry as well as nuclear medical diagnostics and therapy. The operating business is divided into two segments:
Notice: These images may only be used for the purpose of editorial reporting. Any other use and disclosure to third parties is prohibited. Eckert & Ziegler retains the rights of use under copyright law. Whenever an image is used, ‘Press Photo Eckert & Ziegler’ must be cited as the source.
The page lists Eckert & Ziegler’s executive and supervisory bodies and their strategic leadership roles.
Eckert & Ziegler Group provides isotope technology for medical, scientific, and industrial applications. Founded in 1997, it traces its origins to the Zentralinstitut für Isotopentechnik. Its shares (ISIN DE0005659700) trade on the TecDAX index.
Declaration on the Corporate Governance Code, as per §161 of the German Stock Companies Law (AktG):
The page offers corporate governance details for Eckert & Ziegler SE, including auditor information and remuneration.
Directions / Transport Links From the Hauptbahnhof (Central Station) / City Center By public transportation:
Eckert & Ziegler SE Robert-Rössle-Str. 10 13125 Berlin Germany
Eckert & Ziegler SE is headquartered at Robert-Rössle-Str. 10, D-13125 Berlin.
Disclaimer of Liability This website is operated by Eckert & Ziegler SE (‘Eckert & Ziegler’), based in Berlin, Germany, and is intended for international users.
Eckert & Ziegler and TerThera have signed a supply agreement to deliver **next-generation GMP-compliant Terbium-161 radiopharmaceutical therapies** to patients in Brazil. The partnership expands access to advanced nuclear medicine treatments under Eckert & Ziegler’s global nuclear medicine platform. TerThera specializes in innovative radioligand therapies for targeted cancer treatments.
Oct 2026TertheraNews article
Eckert & Ziegler reports steady progress in its first-half 2026 performance. The company maintains momentum in its core markets, though specific financial or operational details are not disclosed. Leadership emphasizes continued execution against strategic priorities amid evolving industry conditions.
Aug 2026finanzen.netNews article
Molecular Partners partners with Eckert & Ziegler to advance its pipeline of Radio-DARPin therapeutics. The collaboration focuses on imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac). This agreement accelerates development of wholly-owned targeted alpha radiotherapeutics for potential medical applications.
Feb 2026Molecular PartnersNews article
Eckert & Ziegler secures a reservation agreement with PharmaLogic Holdings to supply the therapeutic radioisotope **Actinium-225 (Ac-225)**. The deal formalizes the provision of this medical isotope, which is used in targeted cancer therapies. Both companies specialize in nuclear medicine and radiopharmaceuticals, expanding their collaborative efforts in advanced healthcare solutions.
Oct 2023AuntMinnieEuropeNews article